WYC-209|cas:2131803-90-0|西域试剂

WYC-209,98.68%

产品编号：Bellancom-124136| CAS NO：2131803-90-0| 分子式：C₂₀H₂₀N₂O₃S| 分子量：368.45

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124136	￥3900.00	杭州北京（现货）
Bellancom-124136	￥6500.00	杭州北京（现货）
Bellancom-124136	￥0.00	杭州北京（现货）
Bellancom-124136	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

WYC-209

产品介绍

WYC-209，一种合成类视黄醇，是维甲酸受体 (RAR)激动剂。WYC-209 主要通过 caspase 3 途径诱导 TRC 凋亡，抑制恶性小鼠黑色素瘤肿瘤再生细胞的 IC₅₀ 值为 0.19 μM，具有长期效应且毒性小。

生物活性

WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC₅₀=0.19 μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity.

体外研究

WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	A2780, A549, MCF-7, MDA-MB-435s, A375 cells
Concentration:	10 μM
Incubation Time:	24 hours
Result:	TRCs failed to resume growth 5 days after the drug washout.

体内研究
(In Vivo)

WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immune-competent C57BL/6 mice
Dosage:	0.022, 0.22 mg/kg
Administration:	Intravenous injection; once every two days for 25 days
Result:	Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.

体内研究

WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immune-competent C57BL/6 mice
Dosage:	0.022, 0.22 mg/kg
Administration:	Intravenous injection; once every two days for 25 days
Result:	Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.

体内研究

WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immune-competent C57BL/6 mice
Dosage:	0.022, 0.22 mg/kg
Administration:	Intravenous injection; once every two days for 25 days
Result:	Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 83.33 mg/mL (226.16 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7141 mL	13.5704 mL	27.1407 mL
5 mM	0.5428 mL	2.7141 mL	5.4281 mL
10 mM	0.2714 mL	1.3570 mL	2.7141 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.65 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.65 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.65 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。